Bicara Therapeutics Inc. (BCAX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bicara Therapeutics Inc. (BCAX:NASDAQ), powered by AI.

Current Price
$21.69
P/E Ratio
-8.6
Market Cap
1.2B
Sector
Healthcare
What is the Bicara Therapeutics Inc. stock price forecast?

Bicara Therapeutics Inc. is currently trading at $21.69. View real-time AI analysis on Alpha Lenz.

What is Bicara Therapeutics Inc. insider trading activity?

View the latest insider trading data for Bicara Therapeutics Inc. on Alpha Lenz.

What is Bicara Therapeutics Inc.'s P/E ratio?

Bicara Therapeutics Inc.'s P/E ratio is -8.6.

Bicara Therapeutics Inc.

NASDAQ · BCAX
$21.69+0.41(+1.93%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Bicara Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Bicara Therapeutics Inc. trades at a P/E of -8.6 (undervalued) with modest ROE of -30.9%.

Ask for details

Company Overview

Bicara Therapeutics Inc. is a biotechnology company focused on the development of innovative therapies for cancer treatment. The company primarily aims to enhance the effectiveness of immunotherapies by using multi-functional antibodies that modulate the tumor microenvironment. These pioneering therapies are designed to target complex and challenging cancers, potentially offering patients new avenues for treatment. Bicara Therapeutics operates within the rapidly growing biotechnology sector, where advancements in immuno-oncology and personalized medicine are significantly impacting cancer treatment protocols. The company's efforts contribute to a larger industry shift towards more targeted and effective biologic drugs, aiming to improve efficacy while reducing adverse effects commonly associated with conventional cancer treatments. Headquartered in the United States, Bicara Therapeutics plays an essential role in advancing cancer research and therapy by pushing the boundaries of current medical technologies in oncology.

CEODr. Claire Mazumdar Clemon M.B.A., Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees55

Company Statistics

FY 2025

Profile

$1.19BMarket Cap
$0.00Revenue
0.00Shares Out
55Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-8.60P/E
2.95P/B
N/AEV/Sales
-7.02EV/EBITDA
-11.07P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-29.32%ROA
-30.88%ROE
-33.07%ROIC

Financial Health

$96.69MCash & Cash Equivalents
$-67.14MNet Debt
7.36%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Bicara Therapeutics Inc. (ticker: BCAX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 55 employees. Market cap is $1.2B.

The current price is $21.69 with a P/E ratio of -8.6x and P/B of 2.95x.

ROE is -30.88%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Bicara Therapeutics Inc. (BCAX) Stock Forecast 2026 $21.69 — Price, Financials & Analyst Targets | Alpha Lenz